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153 Early Pseudomonas aeruginosa infection: is susceptibility
testing justiﬁed?
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D. Dolce2, G. Taccetti2. 1University of Edinburgh Medical School, Edinburgh,
United Kingdom; 2CF Center Meyer Hospital, Florence, Italy
Background: Once chronic infection with Pseudomonas aeruginosa is established,
the clinical value of conventional susceptibility testing is questionable. It has also
been suggested that testing of early isolates may also be unnecessary based on the
presumption these bacteria are consistently susceptible.
Aims: To determine if P. aeruginosa associated with early infection are invariably
susceptible to antimicrobials used in early treatment.
Methods: We investigated environmental isolates as a major source of early
infection and early clinical isolates from CF patients who had previously been
pseudomonas-free; additional criteria included a nonmucoid morphotype. Clonality
was excluded by PFGE. To date, susceptibility of 58 environmental isolates and
37 early clinical isolates from 37 patients has been analysed by Etest (bioMerieux
UK Ltd, Basingstoke) and CSLI breakpoints based on parenteral delivery. Variable
susceptibility within clonal isolates from individual sputa was investigated in
53 additional early isolates from 6 patients.
Results: All environmental isolates proved susceptible to colistin, ciproﬂoxacin,
tobramycin, ceftazidime, amikacin and meropenem. However, ~10% of early clinical
isolates were resistant to at least one antibiotic. Multiresistance was not observed.
Conclusion: The susceptibility of P. aeruginosa responsible for early infection
cannot be presumed. Clinical studies focused on early infection are necessary to
assess the continued validity of testing, and to identify breakpoints appropriate to
aerosol delivery. Meanwhile, susceptibility testing should be continued for early
infection.
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Introduction and Aims: P. aeruginosa is frequently detected as a causative
pathogen of pulmonary infection in patients with both CF and non-CF bronchiec-
tasis. This study aimed to compare the antimicrobial susceptibility of P. aeruginosa
cultured from CF and non-CF bronchiectasis patients.
Methods: The susceptibility of 80 P. aeruginosa isolates to 4 antibiotics (cef-
tazidime, meropenem, tobramycin and piperacillin/tazobactam) was determined
using E-test strips with isolates classiﬁed as susceptible, intermediate or resistant
to each antibiotic according to the British Society for Antimicrobial Chemotherapy
guidelines. Of the isolates tested, 49 were cultured from CF and 31 from non-CF
bronchiectasis patients.
Results: Thirty-ﬁve isolates (71.4%) from CF patients were susceptible to all four
antibiotics with no isolates resistant to all 4 agents tested. Resistance to tobramycin
occurred in 6.1% of the CF isolates with greater resistance to ceftazidime (22.4%),
meropenem (20.4%) and piperacillin/tazobactam (14.3%) apparent. In contrast,
28 isolates (90.3%) from patients with non-CF bronchiectasis were susceptible to
all four antibiotics. Furthermore, none of these isolates were resistant to any of the
4 antibiotics tested.
Conclusion: There were higher levels of resistance to antibiotics amongst isolates
from CF patients. This may be due to the fact that antibiotics are prescribed more
frequently and for a longer duration in CF patients compared to patients with non-
CF bronchiectasis.
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Introduction and Aims: Temocillin is increasingly used in the treatment of
P. aeruginosa CF lung infection. This study aimed to compare the susceptibility
of clinical P. aeruginosa isolates cultured from CF sputum to temocillin using
conventional MIC and time-kill assays.
Methods: The susceptibility of 50 clinical P. aeruginosa isolates to temocillin
was determined by E-test. Isolates displaying low (4mg/L, n = 6), intermediate
(8mg/L, n = 3) and high (48–>1024mg/L, n = 3) resistance to temocillin, according
to the MIC breakpoint for enterobacteriaceae, were selected and time-kill studies
performed over 24 hours at temocillin concentrations of 2, 8 and 32mg/L.
Results: The MIC50, MIC90 and range for temocillin was 4, 12 and 0.25–
>1024mg/L, respectively. Temocillin at a concentration of 2mg/L had no effect
on the total viable count of any of the isolates over a 24 hour period. However,
temocillin at a concentration of both 8 and 32mg/L resulted in total kill at 24 hours
for all isolates with low resistance and for 2 of the 3 isolates with intermediate
resistance. In contrast, temocillin, at all concentrations tested, had no effect on the
viable count of the 3 isolates with high resistance.
Conclusion: P. aeruginosa isolates with low or intermediate resistance to temocillin
are killed by temocillin concentrations achievable in vivo. Therefore, the use
of temocillin for treatment of P. aeruginosa pulmonary infection in CF could
potentially be directed by determining the MIC and using the breakpoints for
Enterobacteriaceae.
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Pseudomonas aeruginosa bioﬁlm formation in the airways of patients with cystic
ﬁbrosis (CF) restricts the efﬁcacy of antibiotics leading to chronic infections which
have a large impact on morbidity and mortality. Antibiotic combination therapy
might be more efﬁcient than single antibiotics to combat lung infections in CF.
Patients and Methods: In a pilot study ﬁve adult CF patients, suffering from
chronic P. aeruginosa lung infection were treated with Colistin (1M I.U.) and
Tobi® (300mg) twice daily consecutively for 28 days by inhalation using a
Pari E-ﬂow oder Pari Master. Lung function expressed as expiratory volume in
1 sec (FEV1) and P. aeruginosa colony forming units (CFU) were determined
before and after the study. Rats were challenged intratracheally with alginate beads
containing 1×108 CFU/ml P. aeruginosa PAO1 and then treated with 64× minimal
inhibition concentration (MIC) of colistin, tobramycin or the combination. Lungs
were examined macroscopically and CFU determined after 7 days.
Results: Drug inhalation was well tolerated by all patients. P. aeruginosa CFUs were
signiﬁcantly lower after the study (2.64±2.4 log/ml; p = 0.038) and lung function
increased (2.46±0.9%; p = 0.0012). In the rat experiment lung pathology and
bacterial CFUs (colistin 8×105, tobramycin 1.4×103, colistin/tobramycin 1×102)
were signiﬁcantly lower in animals treated with the antibiotic combination.
Conclusion: The superior efﬁcacy of colistin/tobramycin combinations suggest that
simultaneous combination therapy in CF patients is more efﬁcient than alternative
single antibiotic therapy with these drugs to combat lung infection of P. aerugi-
nosa in CF.
